

Resource Summary Report

Generated by [RRID](#) on Aug 2, 2026

Acetyl-Histone H3 (Lys27) (D5E4) XP Rabbit mAb

RRID:AB_10949503

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 8173, RRID:AB_10949503

Antibody Information

URL: http://antibodyregistry.org/AB_10949503

Proper Citation: Cell Signaling Technology Cat# 8173, RRID:AB_10949503

Target Antigen: Acetyl-Histone H3 (Lys27) (D5E4) XP Rabbit mAb

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W, IF-IC, F, ChIP, ChIP-seq. Consolidation on 11/2018: AB_10949503, AB_10949887, AB_2616015.

Antibody Name: Acetyl-Histone H3 (Lys27) (D5E4) XP Rabbit mAb

Description: This monoclonal targets Acetyl-Histone H3 (Lys27) (D5E4) XP Rabbit mAb

Target Organism: rat, hm, hamster, xenopusamphibian, h, gp, hr, m, horse, mouse, r, zebrafishfish, x, z, human, mk

Antibody ID: AB_10949503

Vendor: Cell Signaling Technology

Catalog Number: 8173

Record Creation Time: 20250819T215642+0000

Record Last Update: 20250820T003618+0000

Ratings and Alerts

- ENCODE PROJECT External validation for lot: 3 is available under ENCODE ID: ENCAB502OHI - ENCODE
<https://www.encodeproject.org/antibodies/ENCAB502OHI>

No alerts have been found for Acetyl-Histone H3 (Lys27) (D5E4) XP Rabbit mAb.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 136 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Barajas JM, et al. (2026) Tandem Duplications in UBTF Create XPO1-Dependent Nuclear Export Signals that Reveal a Leukemic Therapeutic Dependency. Blood cancer discovery, 7(1), 51.

Safari M, et al. (2026) Combined HDAC and eIF4A inhibition: A novel epigenetic therapy for pancreatic ductal adenocarcinoma. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 84, 101312.

Bajikar SS, et al. (2025) Acute MeCP2 loss in adult mice reveals transcriptional and chromatin changes that precede neurological dysfunction and inform pathogenesis. Neuron, 113(3), 380.

Ciuba K, et al. (2025) Molecular signature of primate astrocytes reveals pathways and regulatory changes contributing to human brain evolution. Cell stem cell, 32(3), 426.

Liu XQ, et al. (2025) De novo assembly of nuclear stress bodies rearranges and enhances NFIL3 to restrain acute inflammatory responses. Cell, 188(17), 4586.

Qin LN, et al. (2025) Extrachromosomal DNA biogenesis is dependent on DNA looping and religation by YY1-Lig3-PARYlation complex. Molecular cell, 85(16), 3090.

Zamuner FT, et al. (2025) Epigenetic profiling reveals key super-enhancer networks driving oncogenesis in HPV-positive HNSCC. iScience, 28(11), 113911.

Zheng B, et al. (2025) BRD2 bridges TFIID and MOF-H4K16ac-containing nucleosomes to promote transcriptional initiation. Molecular cell.

Wang W, et al. (2025) Chromatin modification abnormalities by CHD7 and KMT2C loss promote medulloblastoma progression. Cell reports, 44(5), 115673.

Rominger MC, et al. (2025) Mutant RIT1 cooperates with YAP to drive an EMT-like lung cancer state. Cell reports, 44(10), 116185.

Oka T, et al. (2025) Epigenomic regulation of stemness contributes to the low immunogenicity of the most mutated human cancer. Cell reports, 44(5), 115561.

Gao C, et al. (2025) Hypoxia-induced phase separation of ZHX2 alters chromatin looping to drive cancer metastasis. *Molecular cell*, 85(8), 1525.

He X, et al. (2025) PI3K?? functions as a protein kinase to promote cellular protein O-GlcNAcylation and acetyl-CoA production for tumor growth. *Molecular cell*, 85(7), 1411.

Li H, et al. (2025) Mapping chromatin structure at base-pair resolution unveils a unified model of cis-regulatory element interactions. *Cell*, 188(25), 7175.

Li Y, et al. (2025) SIWRKY14 integrates carotenoid and flavonoid biosynthetic pathways to regulate coloration and quality of tomato fruits. *Cell reports*, 44(10), 116369.

Chang J, et al. (2025) Antagonistic roles for MITF and TFE3 in melanoma plasticity. *Cell reports*, 44(4), 115474.

Bird SG, et al. (2025) Regulatory role for tumor suppressor REST on estrogen receptor (ESR1) expression and leiomyoma pathophysiology. *The Journal of biological chemistry*, 302(1), 111017.

Sasaki M, et al. (2025) Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers. *Cancer research communications*, 5(1), 24.

Umeda M, et al. (2025) Fusion oncoproteins and cooperating mutations define disease phenotypes in NUP98-rearranged leukemia. *medRxiv : the preprint server for health sciences*.

Hu W, et al. (2025) High fructose promotes MYCN-amplified neuroblastoma progression through NgBR-ACSS2-mediated biosynthesis of acetyl-CoA. *Cell reports*, 44(7), 115947.